GMAB is quietly outperforming a weak biotech tape this week, even as the teclistamab enrollment cloud from earlier in September continues to hang over the thesis.
The most telling data point right now is not where Genmab's short interest sits — it is where it doesn't. Borrow availability is effectively unconstrained, registering at the ceiling of the data range, with over 11 million shares available to lend and utilization barely above 0.7%. Cost to borrow is holding around 0.63%, essentially unchanged over the past month. That is about as loose as a lending market gets, and it means short sellers are not pressing the stock aggressively. The ORTEX short score of 30.8 — ranked in the 80th percentile for low short pressure — confirms the picture: this is not a name where bears are building a large structural position.
The relative performance this week reinforces that reading. GMAB slipped just 0.7% over the past five sessions, a notably resilient print against a backdrop of broad weakness across its peer group. ABVX dropped 7.1% on the week, fell 7.3%, shed nearly 10%, and lost 11%. Even the more liquid names — and — drifted slightly lower. Genmab's flat-to-down finish in that company stands out. The stock recovered 1.6% on Tuesday alone, suggesting buyers stepped in on weakness.
The Street's baseline remains constructive. The analyst consensus price target runs close to DKK 2,454, roughly 14% above the current close of DKK 2,150. No recent analyst changes are on record in the data — meaning the September 10 note flagging teclistamab enrollment shortfalls has not yet triggered a formal wave of target cuts, even if it dented short-term sentiment. Valuation multiples paint a reasonable picture: the trailing P/E sits near 20.9x, the EV/EBITDA near 13.2x, and both have been broadly stable over the past month. EPS momentum factor scores rank in the 78th-80th percentile on both 30-day and 90-day windows, which tells you the forward earnings revision trend is still positive even if the EPS surprise score (13th percentile) suggests recent beats have not been dramatic. The combination of moderate multiples and upward estimate revisions is what supports the constructive thesis — the stock is not being priced for perfection.
Institutional positioning adds texture. Orbis Investment Management holds 7.2% of shares — the single largest external stake — and was essentially flat through June. BlackRock (6.99%) added modestly through August. The more interesting moves are from AllianceBernstein, which added 458,000 shares in Q2, and Paradigm Biocapital, a specialist biotech fund that added 517,000 shares in the same period. Deerfield Management also put on 440,000 shares. Those are meaningful conviction adds from sector-focused money, and they predate the September teclistamab headlines — the question is whether those managers held through the news or trimmed. Insider activity is not a current driver: the most recent non-compensatory trade in the data is a small board-level sale in late May, and the net 90-day insider share count is essentially flat at -526 shares.
The next hard catalyst arrives early — Genmab's Q3 results are scheduled for October 7. After August's print, the stock gained 5.7% on the day and extended to 7% over five sessions, making it one of the better recent single-day reactions in the data. The May print went the other way, falling 7.2%. With the enrollment headline still fresh and analyst targets not yet formally revised, the October release is set up as a moment where the teclistamab narrative either stabilizes or deteriorates — and that binary makes the degree of any guidance update the number to watch.
See the live data behind this article on ORTEX.
Open GMAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
